Seattle, WANCT07725939Now EnrollingIRB Ready

Chronic Obstructive Pulmonary Disease With Chronic Bronchitis Clinical Trial in Seattle, WA

Access cutting-edge chronic obstructive pulmonary disease with chronic bronchitis treatment through this phase 2 clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by UCB Biopharma SRL

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access chronic obstructive pulmonary disease with chronic bronchitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic obstructive pulmonary disease with chronic bronchitis treatment provided free

Apply for This Seattle Location

Check if you qualify for this chronic obstructive pulmonary disease with chronic bronchitis clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Chronic Obstructive Pulmonary Disease With Chronic Bronchitis Study in Seattle

The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

Sponsor: UCB Biopharma SRL

Who Can Participate

Inclusion Criteria

Participant must be aged ≥40 to ≤80 years of age, inclusive, at the time of signing the Informed Consent form (ICF)
Participant with a documented physician-diagnosed moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with chronic bronchitis phenotype
Participant has a documented record of receiving maintenance inhaled therapy at a stable dose for ≥3 months prior to Screening comprised of: • long-acting beta2 agonist (LABA) +long-acting muscarinic antagonist (LAMA) ±inhaled corticosteroid (ICS)
Participant at a high risk of exacerbations, defined as a documented exacerbation history of ≥2 moderate or severe acute exacerbation(s) of chronic obstructive pulmonary disease (AECOPD) in the 12 months prior to Screening or 1 severe AECOPD in the 6 months prior to Screening
Participant has a Chronic Airways Assessment Test (CAAT) score of ≥15 at Screening
Participant has acceptable inhaler and spirometry techniques according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines during the Screening Visit
Participant can be male or female.
A male participant must agree to use contraception during the Intervention Periods and for at least 60 days after the final dose of study intervention and refrain from donating sperm during this period
A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies:
Not a women of childbearing potential (WOCBP) OR
A WOCBP who agrees to follow the contraceptive guidance during the Intervention Periods and for at least 60 days after the final dose of study intervention
Participant is a current or ex-smoker (with tobacco smoking history of ≥10 pack-years)

Exclusion Criteria

Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
Participant has a history of uncompensated heart failure, fluid overload, or myocardial infarction, or evidence of new onset ischemic heart disease or in the opinion of the investigator other serious cardiac disease, within 12 months prior to Screening
Participant has a presence or a family history (first degree) of inflammatory bowel disease (IBD)
Participant has uncontrolled neuropsychiatric disorder, active suicidal ideation, or positive suicidal behavior
Participant has a history of chronic or recurrent clinically significant infections, or a serious extrapulmonary infection within the 6 months prior to Baseline
Participant has clinically important pulmonary disease other than COPD with chronic bronchitis
Participant has hypercapnia requiring bilevel positive airway pressure (BiPAP)
Participant has had a live or attenuated vaccines within 4 weeks prior to Screening or plans to receive such vaccines during the study
Participant has relevant safety events to one or more interleukin (IL)-13 or IL-17 biologic response modifiers that resulted in discontinuation and change of treatment
Participant has absolute neutrophil count (ANC) \<1.5 × 10³/μL
Participant has a corrected QT interval (QTc) \>450msec for male participants or QTc \>470msec for female participants or QTc \>480 msec in participants with bundle branch block
Participant has a history of past or current chronic alcohol or drug abuse within the previous 12 months

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07725939) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Obstructive Pulmonary Disease With Chronic Bronchitis Treatment Options in Seattle, WA

If you're searching for chronic obstructive pulmonary disease with chronic bronchitis treatment options in Seattle, WA, this clinical trial (NCT07725939) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic obstructive pulmonary disease with chronic bronchitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic obstructive pulmonary disease with chronic bronchitis clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Seattle, WA

See all ulcerative colitis clinical trials recruiting in Seattle — not just this study.

Browse Ulcerative Colitis Trials in Seattle →

Browse More Trials by Condition

Ulcerative Colitis TrialsAnkylosing Spondylitis TrialsCOPD TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA